Sjogren syndrome
Therapeutic area
Immunology
Rare disease
Yes
- Definition
- An autoimmune disorder in which immune cells attack and destroy the glands that produce tears and saliva. Sjögren syndrome is also associated with rheumatic disorders such as rheumatoid arthritis or systemic lupus erythematosus. The hallmark symptoms of Sjögren syndrome are dry mouth and dry eyes. In addition, Sjogren syndrome may cause skin, nose, and vaginal dryness. It also may affect other organs of the body including the kidneys, blood vessels, lungs, liver, pancreas, and brain
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Sjogren syndrome
- Therapeutic area
- Immunology
- Sjogren syndrome
- Sjogren syndrome
- Sjögren syndrome
- Sjögren-Gougerot syndrome
- primary Sjogren-Gougerot syndrome
- primary Sjögren-Gougerot syndrome
- sicca syndrome
- syndrome, Sjogren's
- Disease mechanisms
- Syndromic
- Severity
- Moderate
- Immunology
- Ophthalmology
- MONDO ID
- MONDO:0010030
- Parent condition
- MONDO:0000586
Related records
Broader conditions (15)
- Autoimmune disease
- Autoimmune disorder of exocrine system
- Disease
- Disease by body system or component
- Disorder of lacrimal gland
- Disorder of orbital region
- Disorder of visual system
- Eye adnexa disorder
- Eye disorder
- Human disease
- Immune system disorder
- Lacrimal apparatus disorder
- Mouth disorder
- Salivary gland disorder
- Syndromic disease
Trials (307)
- "Core Stabilization Strenght and Pelvic Floor Functions in Primary Sjogren's"
- "Validity and Reliability of Pelvic Floor Distress Inventory-20 in Primary Sjögren's Syndrome"
- A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
- A Clinical Trial for CTD-ILD Treatment
- A Clinical Trial to Evaluate the Safety and Efficacy of Traditional Chinese Medicine in Sjögren's Syndrome.
- A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
- A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome
- A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study
- A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
- A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases
- A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases
- A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
- A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
- A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
- A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
- A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients
- A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
- A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome
- A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome
- A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
Approved drugs (1)
- Pilocarpine
Drugs in development (51)
- Abatacept Phase 3
- Abiprubart Phase 2
- AMG-557 Phase 2
- Anifrolumab Phase 2
- Baminercept Phase 2
- Baricitinib Phase 2
- Belimumab Phase 2
- Cyclosporine Phase 2
- Dazodalibep Phase 3
- Deucravacitinib Phase 3
- Dexamethasone Phase 2
- Dornase alfa Phase 1
- Efalizumab Phase 2
- Efgartigimod alfa Phase 2
- Etanercept Phase 2
- Filgotinib Phase 2
- Frexalimab Phase 2
- GLPG-3970 Phase 2
- GSK2618960 Phase 1
- Hydroxychloroquine Phase 3
Other linked drugs (2)
- Bromhexine
- Cevimeline